文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu-rhPSMA-10.1(一种新型PSMA靶向治疗药物)的器官与肿瘤剂量学:一项I期试验结果

Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-06

这项I期试验纳入13例经标准治疗后进展的PSMA阳性mCRPC患者,给予≤3周期177Lu-rhPSMA-10.1(5.55或7.40 GBq,间隔6周),用多床位SPECT/CT计算肿瘤和器官吸收剂量。结果示肾脏、唾液腺、肿瘤平均吸收剂量分别为0.266、0.130、8.87 Gy/GBq(活性法),肿瘤-肾脏和肿瘤-唾液腺比值分别为32.1和73.2;肿瘤吸收剂量逐周期下降,第2、3周期较第1周期分别低约37%和约56%。正常器官累积剂量均在已确立的可耐受限值内。

要点

  • 13例PSMA阳性mCRPC患者中,3例接受5.55 GBq/周期,10例接受7.40 GBq/周期。
  • 活性法测得肿瘤平均吸收剂量8.87 Gy/GBq,肿瘤-肾脏和肿瘤-唾液腺比值分别为32.1和73.2。
  • 肿瘤吸收剂量逐周期下降,第2、3周期较第1周期分别低约37%和约56%。

核心结论

  • 177Lu-rhPSMA-10.1因药代动力学良好,可向肿瘤递送高于正常器官的辐射剂量。
  • 正常器官累积剂量均在已确立的可耐受限值内,提示临床试验中可给予更高的累积放射性活度。
  • 肿瘤吸收剂量随后续周期下降的现象支持在II期探索前负荷放射性活度。

研究设计与样本

  • I期试验,纳入标准治疗后进展的PSMA阳性mCRPC患者,接受≤3周期177Lu-rhPSMA-10.1,剂量为5.55或7.40 GBq,间隔6周。
  • 给药后3、24、48和168小时行多床位SPECT/CT以计算肿瘤和器官吸收剂量。
  • 采用活性法和解剖法两种方法选择和勾画肿瘤进行剂量学评估。
  • 给药前30分钟及给药后0.5、1.5、4、24和48小时采集静脉血测定放射性。

主要发现

  • 共纳入13例患者,3例接受5.55 GBq/周期,10例接受7.40 GBq/周期。
  • 肾脏、唾液腺和肿瘤(活性法)平均吸收剂量分别为0.266、0.130和8.87 Gy/GBq。
  • 肿瘤-肾脏和肿瘤-唾液腺平均比值分别为32.1和73.2。
  • 活性法肿瘤剂量估计始终高于解剖法。
  • 肿瘤吸收剂量逐周期下降,第2和第3周期估计值较第1周期分别低约37%和约56%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate tumour and normal organ dosimetry of PSMA-targeted RLT 177Lu-rhPSMA-10.1. METHODS: PSMA-positive mCRPC patients experiencing disease progression following standard-of-care treatment were enrolled and underwent ≤ 3 cycles of 5.55 or 7.40 GBq 177Lu-rhPSMA-10.1 at 6-week intervals. Multi-bed SPECT/CT was conducted 3-, 24-, 48-, and 168-hours post-administration to calculate tumour and organ absorbed doses. Two methods (activity- and anatomy-based) were used for selecting and delineating tumours for dosimetry. Venous blood was collected for radioactivity measurement 30 min before 177Lu-rhPSMA-10.1 administration, and 0.5-, 1.5-, 4-, 24-, and 48-hours post-administration. RESULTS: Thirteen patients were enrolled; three received 5.55 GBq/cycle and 10 received 7.40 GBq/cycle. Mean absorbed doses were 0.266, 0.130 and 8.87 Gy/GBq in kidneys, salivary glands, and tumours (activity-method), respectively, giving mean tumour-to-kidney and tumour-to-salivary ratios of 32.1 and 73.2, respectively. Tumour dose estimates were consistently higher with the activity-method vs. anatomy-method. Tumour absorbed doses decreased each cycle; Cycle 2 and 3 doses were ~ 37% and ~ 56% lower than Cycle 1 estimates, respectively. 177Lu-rhPSMA-10.1 was rapidly cleared from the blood (effective half-life, 2.2 h). Imaging data showed mean effective half-lives to be 91.4, 33.7 and 45.4 h in tumours, kidneys, and salivary glands, respectively. CONCLUSION: 177Lu-rhPSMA-10.1 delivers high radiation doses to tumours vs. normal organs, facilitated by its favourable pharmacokinetics. Cumulative doses to normal organs were well within established tolerable limits, suggesting higher cumulative radioactivity could be administered in clinical trials. The observation of decreasing tumour absorbed dose with subsequent cycles also supports the exploration of front-loading radioactivity in Phase II.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Nagarajah J, Kim H, Nordquist L, et al. Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a Phase I trial. Eur J Nucl Med Mol Imaging. 2025. PMID: 40325261. doi:10.1007/s00259-025-07313-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。